[Skip to Content]
[Skip to Content Landing]

Conference Presentation: Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

In this randomized trial, polymyxin B hemoperfusion treatment plus conventional medical therapy did not reduce mortality at 28 days compared with sham treatment plus conventional medical therapy among patients with septic shock and high endotoxin activity. Phillip Dellinger, MD, MSc, of Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey, presents findings from the EUPHRATES trial at the European Society of Intensive Care Medicine (ESICM) 31st Annual Congress, LIVES 2018, on October 24 in Paris. Used with permission.

Our websites may be periodically unavailable between 7:00pm CT December 9, 2023 and 1:00am CT December 10, 2023 for regularly scheduled maintenance.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Close
Close

Name Your Search

Save Search
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close